Dunhill Financial’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Dunhill Financial’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-36	Closed	-$1.38K	–	953
2024 Q2	$1.38K	Hold	36	–	–	﹤0.01%	643
2024 Q1	$1.39K	Hold	36	–	–	﹤0.01%	578
2023 Q4	$1.51K	Buy	+36	New	+$781	﹤0.01%	507

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

GEA

Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Dunhill Financial's FMED Position: Q3 2024 in Review

Dunhill Financial sold out of Fidelity Disruptive Medicine ETF (FMED) in Q3 2024, closing a stake of 36 shares — an estimated $1.38K sold.

Dunhill Financial first reported a position in FMED in Q4 2023 and held it in 3 quarters. The position peaked at $1.51K in Q4 2023. 7 funds tracked by Wall St. Rank hold FMED as of Q3 2024.

Dunhill Financial reported no remaining Fidelity Disruptive Medicine ETF position as of Q3 2024 after selling out during the quarter.
Dunhill Financial sold 36 Fidelity Disruptive Medicine ETF shares in Q3 2024, an estimated $1.38K.
Dunhill Financial first reported a position in Fidelity Disruptive Medicine ETF in Q4 2023 and held it in 3 quarters.
Dunhill Financial's Fidelity Disruptive Medicine ETF position peaked at $1.51K in Q4 2023.
7 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q3 2024.

Based on Dunhill Financial's 13F filing for Q3 2024, filed 15 Nov 2024.